Alternatives to evolocumab
1 same-class SPL records vs evolocumab - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Repatha
How to read a high-report FAERS peer set
evolocumab ranks in the upper FAERS-volume third of the corpus (#43 of 524); 1 same-class peers are listed for field comparison only. Labeled indication field for evolocumab: Repatha helps lower LDL cholesterol (bad cholesterol) in adults and children aged 10 and older.
Top FAERS reaction fields for evolocumab total 114,238 reports across 10 reactions, set beside alirocumab. Counts are exposure-weighted submissions, not per-patient risk.
About evolocumab
Repatha is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack and stroke.
Used for: Repatha helps lower LDL cholesterol (bad cholesterol) in adults and children aged 10 and older. It is used along with diet and exercise. It can help people with high cholesterol or inherited high cholesterol (HeFH and HoFH). Repatha also helps reduce the risk of major heart problems in adults at high risk.
1 PCSK9 Inhibitor peers (wide set)
evolocumab vs alirocumab · FAERS reaction fields
FAERS top-reaction field "Device Difficult To Use" shows the widest count spread between evolocumab and alirocumab in this extract (32,421-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | evolocumab | alirocumab |
|---|---|---|
| Device Difficult To Use | 32,421 | - |
| Drug Dose Omission By Device | 24,327 | - |
| Accidental Exposure To Product | 16,287 | - |
| Injection Site Pain | 10,340 | 1,278 |
| Product Storage Error | 6,630 | - |
| Back Pain | 5,430 | - |
| Myalgia | 5,267 | 1,655 |
| Drug Dose Omission | 4,929 | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
evolocumab FAERS volume vs class peers
FAERS volume band
evolocumab is FAERS corpus rank #43 of 524 (high volume tercile). Top-reaction field total: 114,238.
Frequently Asked Questions
Where does evolocumab sit in FAERS report volume vs PCSK9 Inhibitor peers? ▼
Registry note: FAERS counts are voluntary reports and do not establish causation or risk rates. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for evolocumab: see also the generic vs brand label guide when reading Repatha SPL strings.
Read our methodology - how this data is sourced, computed, and verified.